Navigation Links
Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
Date:9/24/2009

_new' target='_new' href="http://www.cephalon.com/" target="_new">www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, clinical development of NUVIGIL, timing of FDA decisions, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

    Contacts:

    Media
    Sheryl Williams
    610-738-6493
    '/>"/>
SOURCE  Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 

Related medicine technology :

1. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
2. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
3. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
4. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
7. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
8. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Pres. Clinton Announces Commitment From Inter-American Development Bank, Global Network for Neglected Tropical Diseases, and Pan American Health Organization to Mobilize $30 Million to Fight NTDs in the Americas at CGI Conference
11. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Dec. 14 Cardium Therapeutics (NYSE Amex: ... 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment ... Healing: Science and Industry Conference held December 10-13, ... The conference is attended by top industry leaders ... wound healing. Dr. Barbara K. Sosnowski, Cardium,s ...
(Date:12/14/2009)... SKIPPACK, Pa., Dec. 14 At GeoInvesting.com, we ... ) for some time now. Our largest hang up ... Although the Company,s fiscal June 2010 net income guidance ... fiscal 2009 reported net income of $7.9 million, the ... term EPS growth scenario, which depends upon the share ...
(Date:12/14/2009)... HELSINKI, Dec. 14 Cancer patients in ... with the introduction of RapidArc® radiotherapy technology from ... at the only private radiotherapy clinic in the ... are using this fast and precise form of ... and cancers of the abdomen and prostate. ,, ...
Breaking Medicine Technology:Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 2Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 3Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 4GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3Time to Turn the Town Pink 57587 1Time to Turn the Town Pink 57587 2Dey L P Settles State of Utah Pricing Litigation 57583 1Dey L P Settles State of Utah Pricing Litigation 57583 2The Lustgarten Foundation Expresses Condolences as Pancreatic Cancer Claims Life of Myles Brand 57580 1
... - ORENCIA is a First-in-Class Biologic Treatment Option Now Available ... Use in Pediatric Patients with ... Company (NYSE: BMY ) today announced that the U.S. ... signs,and symptoms in pediatric patients six years and older with ...
... Inc. (Nasdaq: ARNA ) announced today that ... of APD125 in patients with primary,insomnia. APD125 is ... the,potential to reduce insomnia symptoms and improve sleep ... APD125 is a double-blind, randomized, placebo-,controlled subjective study ...
Other Medicine Technology:U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 2Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 3Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 4Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 5
(Date:12/14/2009)... found simple activities like housework, gardening replaced tube watching ... was watching 25 or 26 hours of television a ... him to cut his tube time in half. , ... more calories each day, and not necessarily through strenuous ... Much of his newly freed time was spent reading ...
(Date:12/14/2009)... , ... La Jolla, Calif. (Vocus) -- The physicians at ... the new chief of staff of the 372-bed facility. Dr. Sedwitz ... Jan. 1, 2010. , , , , ,During his two-year term, ... Jolla’s administrative staff and its board of directors. Dr. Sedwitz will ...
(Date:12/14/2009)... Skilled nursing facilities (SNFs) in Ohio are ... to deal with a 92 percent increase in the ... to $12.01 per bed per day, scheduled for December ... will pay an additional $17,520 to the state each ... of $438,365 yearly. ,, Nearly 96 percent of skilled ...
(Date:12/14/2009)... of Tens of Thousands of New Chronic Hepatitis ... -- Legislation approved by Congress providing for federal ... helping to reduce tens of thousands of new ... United States, the National Viral Hepatitis Roundtable ... included in the FY 2010 Consolidated Appropriations bill ...
(Date:12/14/2009)... WASHINGTON, Dec. 14 The Hemophilia Federation ... ongoing labor issues involving the Teamsters Local 929 ... Jersey. The national blood system depends on skilled ... The blood is distilled into products such as ... von Willebrand disease. ,, The Division of ...
Breaking Medicine News(10 mins):Health News:Cutting TV Time Burns More Calories 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 2Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 3Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2Health News:HFA Voices Blood Safety Concerns 2
... Inc. today,announced the first true single port laparoscopic ... Medical Center, Springfield, MA, Dr. David Earle, Director,of ... a single 12mm access port in the umbilicus ... that does not rely on gaskets,or seals. This ...
... and Adults With ... Disabilities, ... results of its 27th annual ,Cones for Kids, Valentine,s Day,fundraiser to ... have raised just over $616,000 to help,children and adults with disabilities ...
... April 4, 2008 Eli Lilly and Company,(NYSE: ... Commission has approved a new,indication for FORSTEO(R) (teriparatide ... with sustained, systemic,glucocorticoid therapy in women and men ... initial positive opinion issued in February by,the Committee ...
... Recording Artist Chaka Khan, LOS ANGELES, April ... 1-millionth visitor to BODY WORLDS today. This marks,the ... run for BODY WORLDS,at the California Science Center ... Khan and a group of middle school,students from ...
... study finds aftereffects reverberate long after the incidents , , ... victims of male partner violence suffer a wide range ... Health Organization study that included 25,000 women in 11 ... from Bangladesh, Brazil, Ethiopia, Japan, Namibia, Peru, Samoa, Serbia ...
... is,pleased to join Harvard University,s Ash Institute for ... bi-annual conference,Frontiers of Innovation: 20 Years of Innovation ... On Monday evening, the executive,director of the Pan ... discussed multisector partnerships in tackling neglected,diseases and in ...
Other Medicine News:Health News:SurgiQuest Announces First Procedure Using AirSeal(TM) Access System 2Health News:Friendly's Dishes Out $616,000 for Easter Seals 2Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 2Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 3Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 4Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 5Health News:California Science Center Welcomes 1-Millionth BODY WORLDS Visitor 2Health News:Male Partner Violence Hurts Women's Health Worldwide 2Health News:PAHEF Discusses Neglected Diseases and Disaster Preparedness with Innovative Leaders 2
...
...
...
Tip is bent towards port for downward irrigation. 25G x 7/8in (.50 x 16mm)...
Medicine Products: